Robert S. Landsman

Array ( [id] => 10268332 [patent_doc_number] => 20150153329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS' [patent_app_type] => utility [patent_app_number] => 14/616295 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 3562 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10338674 [patent_doc_number] => 20150223679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'BLUE LIGHT-ACTIVATED ION CHANNEL MOLECULES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/616228 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18845 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16306604 [patent_doc_number] => 10775388 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Methods of using antibodies to determine periostin levels in a sample [patent_app_type] => utility [patent_app_number] => 15/106223 [patent_app_country] => US [patent_app_date] => 2015-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 50251 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15106223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106292 [patent_doc_number] => 09862762 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibodies which bind human periostin' [patent_app_type] => utility [patent_app_number] => 15/104502 [patent_app_country] => US [patent_app_date] => 2015-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 54040 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15104502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11635120 [patent_doc_number] => 09657080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-23 [patent_title] => 'Methods for treating diseases with peptides that inhibit IGF-1' [patent_app_type] => utility [patent_app_number] => 14/610356 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6401 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14610356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10405275 [patent_doc_number] => 20150290284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/603691 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16785 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13053783 [patent_doc_number] => 10048277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof [patent_app_type] => utility [patent_app_number] => 15/113599 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24091 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 352 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12962629 [patent_doc_number] => 09873725 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => Mimetic peptides which modulate L-type calcium channels [patent_app_type] => utility [patent_app_number] => 15/120700 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6188 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318572 [patent_doc_number] => 20150203575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'PILR ALPHA INTERACTIONS AND METHODS OF MODIFYING SAME' [patent_app_type] => utility [patent_app_number] => 14/598870 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 18304 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14598870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10435773 [patent_doc_number] => 20150320785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'METHODS USED TO IDENTIFY AND TREAT GLIOBLASTOMA' [patent_app_type] => utility [patent_app_number] => 14/595423 [patent_app_country] => US [patent_app_date] => 2015-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 17518 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14595423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15951125 [patent_doc_number] => 10663462 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Method of treating vascular insulin resistance in a normoglycemic subject based on biomarkers [patent_app_type] => utility [patent_app_number] => 14/592611 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19523 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10299138 [patent_doc_number] => 20150184137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-02 [patent_title] => 'AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/584555 [patent_app_country] => US [patent_app_date] => 2014-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19450 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14584555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10051000 [patent_doc_number] => 09090867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-28 [patent_title] => 'Fed-batch method of making anti-TNF-alpha antibody' [patent_app_type] => utility [patent_app_number] => 14/570685 [patent_app_country] => US [patent_app_date] => 2014-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 46477 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14570685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10032683 [patent_doc_number] => 09073988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-07 [patent_title] => 'Fed batch method of making anti-TNF-alpha antibodies' [patent_app_type] => utility [patent_app_number] => 14/563993 [patent_app_country] => US [patent_app_date] => 2014-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 46816 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14563993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10225740 [patent_doc_number] => 20150110734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'TRAIL SINGLE CHAIN MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/558681 [patent_app_country] => US [patent_app_date] => 2014-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13983 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14558681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12009702 [patent_doc_number] => 09803008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-31 [patent_title] => 'Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)' [patent_app_type] => utility [patent_app_number] => 15/039606 [patent_app_country] => US [patent_app_date] => 2014-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 69 [patent_no_of_words] => 30150 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15039606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419876 [patent_doc_number] => 20170028020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION' [patent_app_type] => utility [patent_app_number] => 15/038953 [patent_app_country] => US [patent_app_date] => 2014-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10357 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15038953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166151 [patent_doc_number] => 09884915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Antibodies against CCR9 and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 15/032475 [patent_app_country] => US [patent_app_date] => 2014-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 13 [patent_no_of_words] => 32587 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15032475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347541 [patent_doc_number] => 20150232547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/551782 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 18171 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14551782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11678328 [patent_doc_number] => 09676844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-13 [patent_title] => 'Pharmaceutical compositions comprising DENND1A variant 2 and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 15/036119 [patent_app_country] => US [patent_app_date] => 2014-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 53 [patent_no_of_words] => 22635 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036119 [rel_patent_id] =>[rel_patent_doc_number] =>)